aFGF	human acidic fibroblast growth factor;
AMD	age-related macular degeneration;
ARPE-19	human retinal pigment epithelial cell line;
BAB	blood-aqueous barrier;
BAC	benzalkonium chloride;
BBB	blood-brain barrier;
BRB	blood-retina barrier;
CD	cyclodextrin;
CMCS	carboxymethyl chitosan;
CNV	choroidal neovascularization;
CPP	cell penetrating peptide;
DEX	dexamethasone;
DME	diabetic macular edema;
DR	diabetic retinopathy;
EDTA	Ethylenediaminetetraacetic acid;
ELISA	enzyme-linked immunosorbent assay;
Es	endostatin;
EtE	efficiency for traversing eye to retina;
FA	fluorescein angiography;
GCL	ganglion cell layer;
HA	hyaluronic acid;
HCEC	human corneal epithelial cells;
HIV	human immunodeficiency virus;
HPLC	high performance liquid chromatography;
HUVEC	human umbilical vein endothelial cells;
IC50	half maximal inhibitory concentration;
IHC	immunohistochemistry;
ILM	inner limiting membrane;
INL	inner nuclear layer;
IPL	inner plexiform layer;
IR	ischemia–reperfusion;
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide;
HConEpic	human conjunctival epithelial cells;
OCT	optical coherence tomography;
OIR	oxygen-induced retinopathy;
ONL	outer nuclear layer;
OPL	outer plexiform layer;
PACAP	pituitary adenylate cyclase activating polypeptide;
PAMAM	poly(amidoamine);
PE	penetration enhancer;
PEG	polyethylene glycol;
PLGA	poly(lactic-co-glycolic acid);
POD	peptide for ocular delivery;
PPII	polyproline type II;
pRFP	red fluorescent protein plasmid;
PRISMA	preferred reporting items for systematic reviews and meta-analyses;
PTD	protein transduction domain;
RCT	randomized controlled trial;
RGC	retinal ganglion cells;
RGD	arginine-glycine-aspartic;
RNV	retinal neovascularization;
RoB	risk of bias;
RPE	retinal pigment epithelium;
TAT	transactivator of transcription;
TUNEL	terminal deoxynucleotidyl transferase dUTP nick end labelling;
VEGF	vascular endothelial growth factor;
VIP	vasoactive intestinal peptide.